Epinephrine nasal spray for the treatment of anaphylaxis: perspectives in pediatrics.

IF 2.6 4区医学 Q2 ALLERGY

Current Opinion in Allergy and Clinical Immunology Pub Date : 2025-09-17 DOI:10.1097/ACI.0000000000001109

Giada Crescioli, Mattia Giovannini, Benedetta Pessina, Simona Barni, Antonella Muraro, Alfredo Vannacci, Francesca Mori

{"title":"Epinephrine nasal spray for the treatment of anaphylaxis: perspectives in pediatrics.","authors":"Giada Crescioli, Mattia Giovannini, Benedetta Pessina, Simona Barni, Antonella Muraro, Alfredo Vannacci, Francesca Mori","doi":"10.1097/ACI.0000000000001109","DOIUrl":null,"url":null,"abstract":"Purpose of review: Anaphylaxis is a severe allergic reaction characterized by a rapid onset and can be potentially life-threatening. Epinephrine is considered the first-line treatment, and until recently, it was available only for intramuscular injection. A new intranasal epinephrine delivery device has now been approved for use in adults and children, offering a needle-free option for emergency treatment of allergic reactions. This narrative review explores its technical characteristics, along with its pharmacokinetic, pharmacodynamic, and safety profiles based on the results of the most recent clinical trials.Recent findings: The key advantages of the intranasal route, including the elimination of needle-length variability, reduced risk of administration errors in obese or underweight patients, and simplified storage requirements, are also discussed. According to recent research, intranasal epinephrine represents an easy-to-use, effective, and well tolerated treatment for severe allergic reactions. Intranasal delivery may offer a painless, easy-to-use, and reliable solution suitable for healthcare professionals, age-appropriate patients and caregivers.Summary: Based on the current evidence, intranasal epinephrine appears to be a promising, well tolerated option that could significantly improve the accessibility and effectiveness of anaphylaxis management in the pediatric setting.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ACI.0000000000001109","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Anaphylaxis is a severe allergic reaction characterized by a rapid onset and can be potentially life-threatening. Epinephrine is considered the first-line treatment, and until recently, it was available only for intramuscular injection. A new intranasal epinephrine delivery device has now been approved for use in adults and children, offering a needle-free option for emergency treatment of allergic reactions. This narrative review explores its technical characteristics, along with its pharmacokinetic, pharmacodynamic, and safety profiles based on the results of the most recent clinical trials.

Recent findings: The key advantages of the intranasal route, including the elimination of needle-length variability, reduced risk of administration errors in obese or underweight patients, and simplified storage requirements, are also discussed. According to recent research, intranasal epinephrine represents an easy-to-use, effective, and well tolerated treatment for severe allergic reactions. Intranasal delivery may offer a painless, easy-to-use, and reliable solution suitable for healthcare professionals, age-appropriate patients and caregivers.

Summary: Based on the current evidence, intranasal epinephrine appears to be a promising, well tolerated option that could significantly improve the accessibility and effectiveness of anaphylaxis management in the pediatric setting.

查看原文本刊更多论文

肾上腺素鼻喷雾剂治疗过敏反应：在儿科的观点。

回顾目的：过敏反应是一种严重的过敏反应，其特点是发病迅速，可能危及生命。肾上腺素被认为是一线治疗药物，直到最近，它还只能用于肌肉注射。一种新的鼻内肾上腺素输送装置现已被批准用于成人和儿童，为过敏反应的紧急治疗提供了一种无针的选择。这篇叙述性综述探讨了其技术特点，以及基于最新临床试验结果的药代动力学、药效学和安全性概况。最近的发现：鼻内途径的主要优势，包括消除针头长度的可变性，减少肥胖或体重不足患者给药错误的风险，简化储存要求，也进行了讨论。根据最近的研究，鼻内肾上腺素是一种易于使用、有效且耐受性良好的治疗严重过敏反应的方法。鼻内给药可以提供无痛、易于使用和可靠的解决方案，适合医疗保健专业人员、适龄患者和护理人员。总结：根据目前的证据，鼻内肾上腺素似乎是一个有希望的，耐受性良好的选择，可以显著提高儿科过敏反应管理的可及性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Allergy and Clinical Immunology 医学-过敏

CiteScore

5.90

自引率

3.60%

发文量

109

审稿时长

6-12 weeks

期刊介绍： This reader-friendly, bimonthly resource provides a powerful, broad-based perspective on the most important advances from throughout the world literature. Featuring renowned guest editors and focusing exclusively on one to three topics, every issue of Current Opinion in Allergy and Clinical Immunology delivers unvarnished, expert assessments of developments from the previous year. Insightful editorials and on-the-mark invited reviews cover key subjects such as upper airway disease; mechanisms of allergy and adult asthma; paediatric asthma and development of atopy; food and drug allergies; and immunotherapy.